The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Christopher P. Cannon

TIMI Study Group

Cardiovascular Division

Brigham and Women's Hospital

Boston

USA

[email]@partners.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, USA. 2001 - 2010
  • Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, USA. 2008

References

  1. Safety of anacetrapib in patients with or at high risk for coronary heart disease. Cannon, C.P., Shah, S., Dansky, H.M., Davidson, M., Brinton, E.A., Gotto, A.M., Stepanavage, M., Liu, S.X., Gibbons, P., Ashraf, T.B., Zafarino, J., Mitchel, Y., Barter, P. N. Engl. J. Med. (2010) [Pubmed]
  2. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Cannon, C.P., Rhee, K.E., Califf, R.M., Boden, W.E., Hirsch, A.T., Alberts, M.J., Cable, G., Shao, M., Ohman, E.M., Steg, P.G., Eagle, K.A., Bhatt, D.L. Am. J. Cardiol. (2010) [Pubmed]
  3. Balancing the benefits of statins versus a new risk-diabetes. Cannon, C.P. Lancet (2010) [Pubmed]
  4. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Cannon, C.P., Dansky, H.M., Davidson, M., Gotto, A.M., Brinton, E.A., Gould, A.L., Stepanavage, M., Liu, S.X., Shah, S., Rubino, J., Gibbons, P., Hermanowski-Vosatka, A., Binkowitz, B., Mitchel, Y., Barter, P. Am. Heart J. (2009) [Pubmed]
  5. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Cannon, C.P., Kumar, A. Clin. Cornerstone (2009) [Pubmed]
  6. Can the polypill save the world from heart disease?. Cannon, C.P. Lancet (2009) [Pubmed]
  7. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Cannon, C.P. Am. J. Cardiol. (2008) [Pubmed]
  8. Combination therapy in the management of mixed dyslipidaemia. Cannon, C.P. J. Intern. Med. (2008) [Pubmed]
  9. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Cannon, C.P., Giugliano, R.P., Blazing, M.A., Harrington, R.A., Peterson, J.L., Sisk, C.M., Strony, J., Musliner, T.A., McCabe, C.H., Veltri, E., Braunwald, E., Califf, R.M. Am. Heart J. (2008) [Pubmed]
  10. Risk stratification and prognostic factors in the post-myocardial infarction patient. Cannon, C.P., Greenberg, B.H. Am. J. Cardiol. (2008) [Pubmed]
  11. Cardiovascular disease and modifiable cardiometabolic risk factors. Cannon, C.P. Clin. Cornerstone (2008) [Pubmed]
  12. Obesity-related cardiometabolic complications. Cannon, C.P. Clin. Cornerstone (2008) [Pubmed]
  13. Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit. Cannon, C.P. Crit. Pathw. Cardiol (2008) [Pubmed]
  14. Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit. Cannon, C.P. Crit. Pathw. Cardiol (2008) [Pubmed]
  15. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. Cannon, C.P., Husted, S., Harrington, R.A., Scirica, B.M., Emanuelsson, H., Peters, G., Storey, R.F. J. Am. Coll. Cardiol. (2007) [Pubmed]
  16. High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. Cannon, C.P. Clin. Cornerstone (2007) [Pubmed]
  17. Cardiovascular disease and modifiable cardiometabolic risk factors. Cannon, C.P. Clin. Cornerstone (2007) [Pubmed]
  18. Introduction: rationale for tight control of hyperglycemia. Cannon, C.P. Am. J. Cardiol. (2007) [Pubmed]
  19. Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy. Cannon, C.P., McLean, D.S. Am. J. Cardiol. (2006) [Pubmed]
  20. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Cannon, C.P., Curtis, S.P., Bolognese, J.A., Laine, L. Am. Heart J. (2006) [Pubmed]
  21. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Cannon, C.P., Steinberg, B.A., Murphy, S.A., Mega, J.L., Braunwald, E. J. Am. Coll. Cardiol. (2006) [Pubmed]
  22. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Cannon, C.P., Curtis, S.P., FitzGerald, G.A., Krum, H., Kaur, A., Bolognese, J.A., Reicin, A.S., Bombardier, C., Weinblatt, M.E., van der Heijde, D., Erdmann, E., Laine, L. Lancet (2006) [Pubmed]
  23. Evolving management of ST-segment elevation myocardial infarction: update on recent data. Cannon, C.P. Am. J. Cardiol. (2006) [Pubmed]
  24. Clinical trials update from the annual scientific session of the American College of Cardiology 2006. Cannon, C.P., Bhatt, D.L. Am. J. Cardiol. (2006) [Pubmed]
  25. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. Cannon, C.P., Braunwald, E., McCabe, C.H., Grayston, J.T., Muhlestein, B., Giugliano, R.P., Cairns, R., Skene, A.M. N. Engl. J. Med. (2005) [Pubmed]
  26. Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. Cannon, C.P., Mehta, S.R., Aranki, S.F. Ann. Thorac. Surg. (2005) [Pubmed]
  27. Acute coronary syndromes: risk stratification and initial management. Cannon, C.P. Cardiol. Clin (2005) [Pubmed]
  28. What is the optimal timing of clopidogrel in acute coronary syndromes?. Cannon, C.P. Crit. Pathw. Cardiol (2005) [Pubmed]
  29. Update to International Classification of Diseases, 9th Revision codes: distinguishes STEMI from NSTEMI. Cannon, C.P. Crit. Pathw. Cardiol (2005) [Pubmed]
  30. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R., Joyal, S.V., Hill, K.A., Pfeffer, M.A., Skene, A.M. N. Engl. J. Med. (2004) [Pubmed]
  31. Utilization of guidelines and computer-based technology to achieve optimal care in atherothrombotic vascular disease. Cannon, C.P. J. Thromb. Thrombolysis (2004) [Pubmed]
  32. Risk stratification and the management of non-ST-segment elevation acute coronary syndromes: the role of antiplatelet therapy. Cannon, C.P. Crit. Pathw. Cardiol (2004) [Pubmed]
  33. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial. Cannon, C.P. J. Am. Coll. Cardiol. (2003) [Pubmed]
  34. Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways. Cannon, C. J. Invasive. Cardiol (2003) [Pubmed]
  35. Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy. Cannon, C.P., Turpie, A.G. Circulation (2003) [Pubmed]
  36. Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapies. Cannon, C.P. Am. J. Geriatr. Cardiol (2003) [Pubmed]
  37. Oral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I. Cannon, C.P. Clin. Cardiol (2003) [Pubmed]
  38. Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part II. Cannon, C.P. Clin. Cardiol (2003) [Pubmed]
  39. The next step in cardiovascular protection. Cannon, C.P. Atheroscler. Suppl (2003) [Pubmed]
  40. Treatment algorithms and critical pathways for acute coronary syndromes. Cannon, C.P. Semin. Vasc. Med (2003) [Pubmed]
  41. Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) acute coronary syndromes Critical Pathway Toolkit. Cannon, C.P., Braunwald, E. Crit. Pathw. Cardiol (2003) [Pubmed]
  42. PROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndrome. Cannon, C.P. Crit. Pathw. Cardiol (2003) [Pubmed]
  43. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Cannon, C.P., McCabe, C.H., Belder, R., Breen, J., Braunwald, E. Am. J. Cardiol. (2002) [Pubmed]
  44. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Cannon, C.P. Am. J. Cardiol. (2002) [Pubmed]
  45. Critical pathway for unstable angina and non-ST elevation myocardial infarction: February 2002. Cannon, C.P. Crit. Pathw. Cardiol (2002) [Pubmed]
  46. Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. Cannon, C.P., Bahit, M.C., Haugland, J.M., Henry, T.D., Schweiger, M.J., McKendall, G.R., Shah, P.K., Murphy, S., Gibson, C.M., McCabe, C.H., Antman, E.M., Braunwald, E. Crit. Pathw. Cardiol (2002) [Pubmed]
  47. How to develop a critical pathway: the acute coronary syndromes: Acute Cardiac Team to Implement Optimal Treatments Now (ACS ACTION) Program. Cannon, C.P., Ornato, J.P. Crit. Pathw. Cardiol (2002) [Pubmed]
  48. Palm Pilot programs to improve quality of care in acute coronary syndromes. Cannon, C.P. Crit. Pathw. Cardiol (2002) [Pubmed]
  49. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. Cannon, C.P., Weintraub, W.S., Demopoulos, L.A., Vicari, R., Frey, M.J., Lakkis, N., Neumann, F.J., Robertson, D.H., DeLucca, P.T., DiBattiste, P.M., Gibson, C.M., Braunwald, E. N. Engl. J. Med. (2001) [Pubmed]
 
WikiGenes - Universities